IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-17703-6.html
   My bibliography  Save this article

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Author

Listed:
  • David Simon

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Koray Tascilar

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Gerhard Krönke

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Arnd Kleyer

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Mario M. Zaiss

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Franz Heppt

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Christine Meder

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Raja Atreya

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Entcho Klenske

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Peter Dietrich

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg)

  • Abdullah Abdullah

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Thorsten Kliem

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Giulia Corte

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Harriet Morf

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Moritz Leppkes

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Andreas E. Kremer

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Andreas Ramming

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Milena Pachowsky

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Florian Schuch

    (Rheumatology Clinical Practice Erlangen)

  • Monika Ronneberger

    (Rheumatology Clinical Practice Erlangen)

  • Stefan Kleinert

    (Rheumatology Clinical Practice Erlangen)

  • Clara Maier

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Axel J. Hueber

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    Sozialstiftung Bamberg)

  • Karin Manger

    (Rheumatology Practice Bamberg)

  • Bernhard Manger

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Carola Berking

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Matthias Tenbusch

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Klaus Überla

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Michael Sticherling

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Markus F. Neurath

    (FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

  • Georg Schett

    (Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen
    FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen)

Abstract

Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.

Suggested Citation

  • David Simon & Koray Tascilar & Gerhard Krönke & Arnd Kleyer & Mario M. Zaiss & Franz Heppt & Christine Meder & Raja Atreya & Entcho Klenske & Peter Dietrich & Abdullah Abdullah & Thorsten Kliem & Giul, 2020. "Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion," Nature Communications, Nature, vol. 11(1), pages 1-7, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17703-6
    DOI: 10.1038/s41467-020-17703-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-17703-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-17703-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17703-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.